Cite
HARVARD Citation
Klein, B. et al. (n.d.). P.020 Long-term safety and tolerability of atogepant 60mg once daily for preventive treatment of migraine: a phase 3, 40-week, multicenter extension to the advance trial. Canadian journal of neurological sciences. p. S13. [Online].